For the study ... show. The findings were published Monday in the Annals of Internal Medicine. There has been a notable uptick in GLP-1 use since 2020, Rezaie noted. The U.S. Food and Drug ...
Semaglutide did not increase the risk of depression, suicidal thoughts or suicidal behavior in people without known mental ...
A total of 77 suicide deaths in GLP-1 agonist users and 71 in SGLT2 inhibitor users were identified. Subgroup analyses ...
If you’ve found yourself unexpectedly humming the tune “Magic” lately, you’re not alone. Thanks to the catchy commercial for ...
A research group led by Prof. Zhu Yingjie from the Shenzhen Institute of Advanced Technology (SIAT) of the Chinese Academy of ...
At least two in five U.S. adults under the age of 65 with "private insurance could be eligible under clinical criteria for GLP-1 drugs," a new KFF analysis shows.
Related Study shows shift in GLP-1 drug use for obesity, not diabetes Weight loss drug Zepbound outperforms Ozempic in new ...
Leo Feler, chief economist and numerator, speaks with NBC News' Christine Romans on his ongoing research on the economic ...
Like its U.S. and European counterparts, Britain’s Medicines and Healthcare Products Regulatory Agency found no conclusive ...
although the latter also appeared to show monomerization of the semaglutide samples similar to the PAGE and SEC analyses. These findings help to build upon Lexaria’s growing dataset ...
Aon found GLP-1 use cost employer health plans $6.25 per member per month in 2023, a 224% increase compared to 2022. The data on spending for 2024 is not yet available, but a study shows GLP-1 ...
Aspen Pharmacare fell short of its targeted mid-single digit growth in core profit on Tuesday, but is betting on GLP-1 drug ...
